History
  • No items yet
midpage
Thermolife International LLC v. Gnc Corporation
922 F.3d 1347
Fed. Cir.
2019
Read the full case

Background

  • Stanford owned four patents (ʼ459, ʼ872, ʼ006, ʼ916) concerning L‑arginine/lysine supplements; ThermoLife obtained exclusive license and filed ~81 infringement suits in 2013, later adding Stanford as co‑plaintiff.
  • District court consolidated the Southern District of California cases, prioritized validity issues, and bifurcated infringement discovery/trial from validity trial.
  • Bench trial on invalidity (Aug 2016) resulted in judgment that all asserted claims of all four patents were invalid for anticipation or obviousness.
  • After judgment, Hi‑Tech and Vital moved for attorney’s fees under 35 U.S.C. § 285, arguing the cases were "exceptional" because ThermoLife/Stanford failed to conduct an adequate pre‑suit investigation (particularly regarding claim 1 of the ʼ459 patent) and sued to extract nuisance settlements.
  • District court struck a late declaration by plaintiffs, found plaintiffs’ pre‑suit investigation objectively unreasonable (labels/advertising contradicted published science showing <1 g L‑arginine ineffective), found a pattern of filing many suits and many small settlements, and awarded fees; the Federal Circuit affirmed.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Whether the case was “exceptional” under § 285 based on inadequate pre‑suit investigation ThermoLife: pre‑suit investigation was adequate; striking of counsel declaration was proper; court should not base fees on unadjudicated infringement Hi‑Tech/Vital: plaintiffs failed to test publicly available products and ignored labels showing <1 g L‑arginine per serving; advertising was an unreliable substitute; pattern of mass filings suggested nuisance settlement strategy Affirmed: district court didn’t abuse discretion; inadequate investigation re: ʼ459 claim 1 supported exceptionality
Whether district court abused discretion by striking Woods declaration submitted after oral argument ThermoLife: declaration described pre‑filing investigation and should have been considered Hi‑Tech/Vital: declaration was untimely and raised new facts and argument denying them discovery opportunity Affirmed: district court acted within discretion to strike untimely declaration
Whether § 285 fee award may rest on an unlitigated/unadjudicated issue (infringement) ThermoLife: basing fees on infringement (not litigated before final judgment) is improper Hi‑Tech/Vital: district courts have latitude to base fees on ill‑supported infringement allegations even if not adjudicated Affirmed: permissible; precedents allow basing fees on inadequately supported infringement allegations with due process respected
Whether lack of early, focused notice by defendants (e.g., Rule 11) bars fees ThermoLife: defendants waited until after merits; lack of early notice should preclude fee award Hi‑Tech/Vital: lack of Rule 11 notice is not dispositive; context (consolidation, phased discovery) matters Affirmed: lack of early formal notice not fatal; § 285 is flexible and district court did not abuse discretion

Key Cases Cited

  • Octane Fitness, LLC v. ICON Health & Fitness, Inc., 572 U.S. 545 (2014) (§ 285 “exceptional” standard: totality of circumstances; substantive strength or unreasonable litigation conduct)
  • Highmark Inc. v. Allcare Health Mgmt. Sys., Inc., 572 U.S. 559 (2014) (appellate review of fee awards is for abuse of discretion)
  • Lumen View Tech. LLC v. Findthebest.com, Inc., 811 F.3d 479 (Fed. Cir. 2016) (affirming fees where infringement allegations were ill‑supported even though non‑infringement had not been adjudicated)
  • Stone Basket Innovations, LLC v. Cook Med. LLC, 892 F.3d 1175 (Fed. Cir. 2018) (early, focused notice by fee‑seeking party is an important consideration in § 285 determinations)
  • SFA Sys., LLC v. Newegg Inc., 793 F.3d 1344 (Fed. Cir. 2015) (repeated filings to force settlements can support finding of litigation abuse under § 285)
Read the full case

Case Details

Case Name: Thermolife International LLC v. Gnc Corporation
Court Name: Court of Appeals for the Federal Circuit
Date Published: May 1, 2019
Citation: 922 F.3d 1347
Docket Number: 2018-1657; 2018-1666
Court Abbreviation: Fed. Cir.